Mouse Anti-TNFRSF10A Recombinant Antibody (clone mAY4) (CAT#: HPAB-1616-FY)

Figure 1 Characterization of the epitope of the humanized hAY4 scFv antibody.

Competitive ELISA. Binding activity of hAY4 scFv (1 M) to plate-coated DR4 was assessed in the presence of serially diluted mAY4 scFv (from 650 nM to 0.9 nM) or TRAIL.

Lee, S. H., Park, D. W., Sung, E. S., Park, H. R., Kim, J. K., & Kim, Y. S. (2010). Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Molecular immunology, 47(4), 816-824.

Figure 2 Biochemical characterization of mouse anti-DR4 AY4 mAb.

Binding specificity of AY4 and TRAIL analyzed by ELISA. ELISA plates were coated with 10 μg/mL of DR4-ECD, DR5-ECD, DcR1-ECD, DcR2-ECD, mTR-ECD, or CD95-ECD and then incubated with 1 μg/mL TRAIL (black columns) or 1 μg/mL AY4 (white columns).

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular cancer therapeutics, 8(8), 2276-2285.

Figure 3 kinetic interactions of AY4 with DR4-ECD determined by SPR analyses.

The injection of DR5-ECD (long dashed line), DcR1-ECD (dotted line), and DcR2-ECD (dash-dotted line) at 2 μmol/L exhibited negligible binding to AY4.

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular cancer therapeutics, 8(8), 2276-2285.

Figure 4 AY4 alone induces cell death of various human cancer cells through cell surface–expressed DR4 without significant cytotoxicity on normal human hepatocytes.

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular ccer therapeutics, 8(8), 2276-2285.

Figure 5 Inhibition of cell death induced by TRAIL (left) or AY4 (right) by the soluble competitor DR4-ECD (black columns) or DR5-ECD (white columns).

Cells were treated with 0.5 μg/mL TRAIL (≈30 nmol/L) or 10 μg/mL AY4 (≈67 nmol/L) for 24 h in the presence of the indicated concentrations (0, 0.04, and 1 μg/mL) of DR4-ECD or DR5-ECD.

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular ccer therapeutics, 8(8), 2276-2285.

Figure 6 AY4 induces caspase-dependent apoptotic cell death of AY4-sensitive cells.

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular ccer therapeutics, 8(8), 2276-2285.

Figure 7 Antitumor effect of anti-DR4 AY4 on growth of preestablished H460 tumors in athymic nude mice.

Comparisons of tumor growth during the treatment at the end of treatment (after 22 d of tumor inoculation) between mice treated with AY4 and IC antibody. After preestablishing of H460 cells with volume of 100 mm3 (day 7), mice (n = 6 per group) were administered i.v. with five doses of AY4 or IC antibody at a single dosage of 5 mg/kg/injection (100 μg/injection) every 3 d from day 7.

Sung, E. S., Park, K. J., Lee, S. H., Jang, Y. S., Park, S. K., Park, Y. H., ... & Kim, Y. S. (2009). A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Molecular ccer therapeutics, 8(8), 2276-2285.